EUEkaterina Leonidovna Urumova

Ekaterina Leonidovna Urumova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ekaterina Leonidovna Urumova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experience with ultrasound-assisted catheter-directed thrombolysis in the treatment of patients with intermediate-high-risk pulmonary embolism

    by M. A. Simakova, S. I. Parkhomenko, K. B. Lapshin, T. D. Glebovskaya, V. S. Krasnov, D. V. Alekseeva, K. N. Malikov, E. L. Urumova, N. V. Marukyan, O. M. Moiseeva

    Aim. To compare the efficacy and safety of ultrasound-assisted catheter-directed thrombolysis (UACDT) using EkoSonic technology (EKOS Corporation, Bothell, Washington, USA) and a routine conservative approach with anticoagulant therapy (ACT) in patients with pulmonary embolism (PE) at intermediate-high risk for 30-day mortality. Material and methods. This single-center retrospective study included patients with confirmed intermediate-high-risk PE with thrombosis of the main or lobar branches of the pulmonary artery, no more than 14 days old. The patients were admitted to the cardiology intensive care units of the Almazov National Medical Research Center between January and December 2025. In accordance with the applied treatment strategy, patients were divided into 2 following groups: the UACDT group using EkoSonic technology (EKOS Corporation, Bothell, Washington, USA) and the ACT group. After 48 hours, the effectiveness of the treatment was assessed as follows: the incidence of decompensated hemodynamics episodes, the changes of right ventricle to left ventricle basal diameter ratio (RV/LV), decrease in the Qanadli score and the increase in residual peripheral flow according to computed tomography pulmonary angiography (CTPA), as well as the changes of right ventricular function echocardiographic parameters. Safety criteria included the incidence of minor and major bleeding. A telephone survey of patients was conducted one month after discharge to assess long-term outcomes. Results. The study included 41 patients, which were divided into 2 groups: ACT group — 21 patients; UACDT group — 20 patients. The endovascular treatment group showed a more pronounced reduction in right heart overload: Δ RV/LV according to CTPA was 0,40 [0,20; 0,70] in the UACDT group vs 0,03 [0,00; 0,40] in the ACT group (p=0,012). A reduction in the RV/LV ratio of more than 20% from baseline was achieved in 74% of cases in the UACDT group vs 30% of cases in the ACT group (p=0,010). According to echocardiography, there was a decrease in the right ventricular diameter by 11,0 [6,7; 13,8] mm in the UACDT group vs 6,0 [1,5; 8,5] mm in the ACT group (p=0,015), a decrease in the right atrial area by 5,20 [0,67; 6,25] cm 2 in the UACDT group vs 0,0 [-1,0; 2,8] cm 2 in the ACT group (p=0,050), a reduction in the inferior vena cava diameter by 2,0 [1,0; 6,0] mm in the UACDT group vs 0,0 [-0,5; 2,0] in the ACT group (p=0,040). In 2 cases (10%) in the UACDT group and in 6 cases (29%) in the conservative ACT group, hemodynamic destabilization was recorded (p=0,238), which served as the basis for "rescue" systemic thrombolytic therapy. Hemorrhagic events occurred in 5 cases (25,0%) in the UACDT group and in 2 cases (9,5%) in the ACT group (p=0,538). The incidence of minor and major bleeding was comparable between the groups as follows: 4 minor bleeding events in the UACDT group vs 2 in the ACT group (p=0,992) and 1 major bleeding event in the UACDT group vs 0 in the ACT group (p>0,999). Fatal outcomes were recorded in 1 case (5%) in the UACDT group and in 3 cases (14%) in the ACT group (p=0,606). Conclusion . There is a higher efficacy of UACDT in the form of a reduction in right ventricular overload in patients with intermediate-high-risk PE when compared with standard ACT with a comparable safety profile.


  • Open Access

    Search for cardiotoxicity predictors of immune checkpoint inhibitors: results of a prospective study

    by M. A. Simakova, N. D. Gavriluk, E. A. Kushnareva, T. N. Shuginova, F. V. Moiseenko, E. L. Urumova, E. V. Karelkina, I. A. Pankova, M. F. Ballyzek, O. M. Moiseeva, et al.

    Поиск предикторов кардиотоксических эффектов ингибиторов контрольных точек иммунитета: результаты проспективного исследования

  • Open Access

    Efficacy of transcatheter low-dose thrombolysis in patients with intermediate-high risk pulmonary embolism. Study rationale and design

    by M. A. Simakova, S. I. Parkhomenko, K. B. Lapshin, T. D. Glebovskay, D. V. Karpova, K. N. Malikov, Ekaterina Leonidovna Urumova, A. V. Berezina, D. D. Zubarev, N. V. Marukyan, et al.

    Aim. Comparison of conservative and invasive treatment strategies in patients with intermediate-high risk pulmonary embolism (PE) based on a multimodal assessment of efficacy and safety.Material and methods. This single-center, open-label, randomized, comparative trial will include 100 patients with a verified diagnosis of PE with intermediate-high risk of 30-day mortality. Patients will be randomized 1:1 to standard anticoagulant therapy or selective low-dose alteplase transcatheter thrombolysis. Patients will be followed for 12 months. The primary endpoint is a decrease in the right ventricle to left ventricle ratio by 20% or more from baseline at 48±6 hours after initiation of therapy. There are secondary endpoints: patient hemodynamic instability; ISTH major bleeding; Qanadli index decrease at 48 hours; degree of residual thrombosis with reduced perfusion at 3-6 months; incidence of post-thromboembolic syndrome at 3-6 months; 30-day, 90-day, and 1-year mortality.Conclusion. The study will provide important clinical data on the short- and long-term efficacy and safety of different treatment approaches in patients with intermediate-to-high-risk acute pulmonary embolism.